Glaxo Settles Relafen Suit for $75 Mln

LOS ANGELES (Reuters) - GlaxoSmithKline Plc, Europe's biggest drug maker, on Wednesday said it will pay $75 million to consumers and health insurers to settle a lawsuit alleging that the company blocked generic competition for arthritis drug Relafen.

Continue to Glaxo Settles Relafen Suit for $75 Mln on Reuters: Health.

Medical Buzz delivers the most recent headlines from the medical world. Diseases, cures, accidents, medicin. Click below for more headlines ...
Medical buzz